Necroptosis is a well-controlled process of programmed necrosis present in inflammatory disorders mainly regulated by RIPK1, RIPK3 and mixed-lineage kinase domain-like pseudokinase (MLKL).
Captor Therapeutics SA has offered an update on its lead programs CT-01, CT-02 and CT-05. In the CT-01 program, CPT-6281 is currently undergoing IND/CTA-enabling studies with the first clinical trial expected to start at the end of the year. The first indication will be in hepatocellular carcinoma (HCC).
Researchers from Atyr Pharma Inc. presented findings from the innovative tRNA synthetase platform, highlighting ATYR-0101, a potential therapeutic biologic based on a domain appended to aspartyl-tRNA synthetase (DARS).
Partially blocking a receptor that helps regulate the activity of the inflammatory cytokine molecule interleukin-6 (IL-6) seems to promote tissue regeneration and block degeneration in a model of osteoarthritis. As reported in the March 22, 2023, issue of Science Translational Medicine, the receptor, called glycoprotein 130 (gp130), regulates both positive and negative inflammatory responses that can help regenerate tissue, but also cause degeneration.
A study from the University Medical Center Hamburg-Eppendorf (UKE) in Germany has identified a type of T cell that triggered glomerulonephritis (GN) and produced loss of kidney function in mice. The scientists described an autoimmune pathway of this disease mediated by the accumulation of T cells producing granulocyte-macrophage colony-stimulating factor (GM-CSF) in the kidneys and found a possible therapeutic target.
Selecta Biosciences Inc. and Swedish Orphan Biovitrum AB unveiled top-line phase III data from the Dissolve I and II trials testing SEL-212 in adults with chronic refractory gout (CRG) – results that position the companies for a regulatory filing in the U.S. during the first half of next year. SEL-212 could take on Horizon Therapeutics plc’s Krystexxa (pegloticase), a pegylated uric acid specific enzyme cleared by the U.S. FDA for CRG in September 2010.
Reistone Biopharma Co. Ltd. has synthesized quinolinofuran derivatives acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of fibrosis, autoimmune, inflammatory and metabolic disorders.
Redx Pharma plc has described henyl- and pyridopyrazole derivatives as discoidin domain-containing receptor DDR1 and/or DDR2 inhibitors. They are reported to be useful for the treatment of fibrosis, cancer, transplant rejection, inflammatory, renal, liver and cardiovascular disorders.
Tetra Bio-Pharma Inc. has received clearance from Health Canada to proceed with a first-in-human trial in Canada using oral ARDS-003 (onternabez) to treat various immunomodulatory conditions. Oral ARDS-003 is positioned to modulate acute systemic inflammation and prevent sepsis, acute respiratory distress syndrome (ARDS) and organ damage.
Researchers from Wenzhou Medical University and affiliated organizations presented the discovery of novel anti-inflammatory agents. Synthesis and optimization of a series of 4-oxo-N-phenyl-1,4-dihydroquinoline-3-carboxamide derivatives led to the identification of compound [I] as the lead, as it exhibited the best inhibitory effect in vitro. More specifically, [I] demonstrated the strongest inhibitory effect on LPS-induced TNF-α (82.58%) and IL-6 (75.05%) expression, while exhibiting no cytotoxicity at 10 μM in J774A.1 macrophages.
RSS
